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Abstract
Coeliac disease (CD) is an autoimmune disorder characterised by inflammation,
villous atrophy and hyperplasia of the small intestinal mucosa that affects
genetically susceptible individuals. A genome-wide scan was performed in 17
family members with high incidence of CD. Highest nonparametric linkage (NPL)
and logarithm of odds (LOD) scores were of 6.21 (P ¼ 0.0107) and 2.57,
respectively, to a region on chromosome 11p13-12. Following fine mapping, NPL
and LOD scores did not change, but the linkage interval on chromosome 11 was
narrowed to a region that is approximately 50.94 cM from pTer. Two inherited
haplotypes on chromosomes 11p13-12 and 9q21 were observed in all affected
members but not in the majority of clinically normal individuals. Sequencing of
genes at region 11p13-12 showed a number of sequence variants, two of which were
linked with the inherited haplotype. One of these variants in the CD59 gene was
found at a very low frequency in the population and could possibly affect pre-
messenger RNA splicing. This study is of particular importance for the iden-
tification of novel genes that might be responsible for CD other than human
leukocyte antigen.
Introduction
Gluten sensitive enteropathy, or coeliac disease (CD)
(OMIM 212750), is a complex disorder with both genetic
and environmental factors playing a role in its pathogenesis.
The disease is characterised by an inflammatory process
triggered in genetically susceptible individuals after the
ingestion of gluten found in wheat, rye and barley, which
leads to complications mostly associated with mucosal
injury and malabsorption (1).
A number of linkage and association studies have been
carried out to try to identify genes that might increase the
individual’s susceptibility for CD. The human leukocyte
antigen (HLA) locus on chromosome 6 was the most
commonly reported locus (2–4), although, recently, linkage
to this region was not confirmed in a large Bedouin family
(5). Other chromosomal loci were identified by genome-
wide linkage scans including 5q31-q33 (6), 10q23, 15q26,
16q23, 19p13.1, 6p12, 2q and 11p11 (7–9), with the latter
being further confirmed in a later study (10). A number of
single nucleotide polymorphisms (SNPs) within candidate
genes were studied for an association with the disease.
A variant within the promoter region of the type II
transmembrane protein (CD209) gene expressed in macro-
phages and dendritic cells was significantly associated with
CD in HLA-DQ2-negative coeliac individuals (11). Poly-
morphisms, within the cytotoxic T lymphocyte (CTL)-
associated-4 (CTLA4) gene, were extensively studied from
which conflicting results were obtained (12, 13). An
extended haplotype within the genes CD28/CTLA4 and
within the gene coding for inducible costimulator (ICOS)
was significantly associated with the disease (12, 14). Other
genes associated with the disease included those coding for
myosin IXB (MYO9B) and CD14, which, although having
different mechanisms, both can affect intestinal permeabil-
ity (15, 16). A genome-wide association study performed in
the UK did not confirmed regions where previously
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associated genes are found (CTLA4 and MYO9B) but
identified a locus on chromosome 4q27 very close to
interleukin 2 (IL2) and IL21 and another predicted gene
of unknown function (KIAA1109) (17). These findings were
later confirmed in Swedish/Norwegian families where it was
concluded that the KIAA1109/Tenr/IL2/IL21 region is
a true susceptibility region for CD (18). A series of novel
regions including IL2-IL21, CCR3 and SH2B3 were re-
cently identified after further follow-up studies of the initial
genome-wide association (19). Other genes were indicated
by gene expression studies performed in normal and
affected individuals with and without a gluten-free diet (20).
In this study, a genome-wide scan was performed in an
extended family with a high incidence of CD to identify
possible chromosomal loci that might contain genes
responsible for the disease. Sequencing of genes at the
indicated locus showed an unreported variant within the
gene coding for protectin (CD59) (MIM107271), whichwas
further studied for its possible effects on pre-messenger
RNA (mRNA) splicing.
Materials and methods
Subjects
Seventeen members (eight males and nine females) from an
extended Maltese family with a high incidence of CD were
recruited for this study (Figure 1). Recruitment was
achieved through the Malta Coeliac Association that
referred interested individuals to the Molecular Genetics
Clinic, Medical School, St Luke’s Hospital, G’Mangia,
Malta.All participantswere asked toanswer aquestionnaire
about their medical history, use of medications, family
history ofCDand adherence to a gluten-free diet. This study
was approved by the Research Ethics Committee, Univer-
sity of Malta, and was funded by the Malta Council for
Science and Technology as part of the Research and
Development (2004) programme.
As shown in Figure 1, the proband of this family was a
58-year-old male (II: 3) who participated in a previous
population study (13) and presented at the clinic with
classical symptoms ofCD. Serological tests showed elevated
antitransglutaminase (tTg), antiendomysium (EmA) and
antigliadin (AGA) immunoglobulin (Ig)A antibodies.
Diagnosis was confirmed by biopsy, which showed histo-
logical features including villous atrophy (Marsh 3)
consistent with CD. Further follow-ups of this patient over
a period of 4 years showed an improvement in serological
results, after he followed a gluten-free diet. Another 16
family members from three generations were recruited, 3 of
whom were diagnosed with CD by biopsy. His 60-year-old
sibling (II: 6) was diagnosed as coeliac 4 years ago when she
had a slightly elevated AGA IgA and IgG, a positive EmA
and a positive anti-tTg (87 U/ml). Gastric and duodenal
Figure 1 Inheritance of STRs on chromosome 11p13. Affected males and females are shown in black shading; females labelled (?) were reported
to have coeliac-like symptoms. Males and females labelled (N) tested individuals showing no evidence of celiac. One-quarter black-shaded individuals
only had high antigliadin (AGA). Markers shown top to bottom are D11S4190, D11S904, D11S914, D11S4101, D11S1392, D11S935, D11S4102 and
D11S1911. Inferred genotypes by GENEHUNTER are in parentheses.
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biopsies showed a chronic gastritis together with villous
atrophy, increased cellularity of the lamina propria and
increased intraepithelial lymphocyte population. This
individual was also instructed to follow a gluten-free diet
after which her serological tests improved. Besides being
coeliac, this individual was also osteoporotic and asthmatic.
She also had a daughter (III: 11) who was possibly affected,
but she was following a gluten-free diet and therefore her
serological tests appeared to be normal. She had symptoms
related to CD and was hospitalised on one occasion after
being admitted with severe epigastric pain and haematem-
esis. Her other aunt (II: 7) had elevated anti-tTg IgA/IgG
and was positive for EmA, while her duodenal biopsy
confirmed villous atrophy that was consistent with coeliac.
A number of follow-ups performed later after she started
a gluten-free diet showed that her anti-tTg and AGA went
down to normal. Another sibling of the proband was also
possibly affected by the condition (individual II: 5) as she
was symptomatic before starting a gluten-free diet. Biopsy
did not show any cellular characteristics related to CD in
this individual, although a weak positive EmA and
borderline AGA IgA were reported.
The proband’s nephew (III: 1) was diagnosed with CD at
the age of 11 years and his intestinal biopsy showed villous
atrophy consistent with coeliac. His serological investiga-
tions showed elevated anti-tTg (217 U/ml), strong positive
EmA and both AGA IgA and IgG were above normal. The
patient was instructed to follow a gluten-free diet and
a follow-up performed 2 years later showed normal biopsy
and serology with only a slightly elevated anti-tTg IgA. His
father (II: 2) and one brother (III: 2) did not have any
symptoms of CD and were not on a gluten-free diet, but
both had slightly elevated AGA IgA or IgG with normal
anti-tTg. Serological tests performed following gluten
challenge, resulted in an increase in AGA IgG, a positive
EmA and positive antireticulin.
Peripheral blood was collected by venipuncture from all
participants for DNA analysis and immunological tests. All
serology was performed at the Immunology Laboratory,
Department of Pathology, St Luke’s Hospital, Malta.
DNA analysis
DNAwas extracted from peripheral blood leucocytes using
a standard laboratory protocol (21). For the initial genome-
wide scan, 400 microsatellite markers spread across the
22 autosomes and x-chromosome with an average spacing
of 8.63 cM and heterozygosity of 0.77 were used. Fine
mapping was performed by increasing the markers at
indicated loci from the initial scan. Genotyping was
performed by polymerase chain reaction (PCR) followed
by fragment analysis using a 3730xl ABI genetic analyser
(Applied Biosystems, Foster City, CA). The average
performance of the markers was of 96.02%. Genotyping
was performed commercially at the McGill University and
Genome Quebec Innovation Centre, Quebec, Canada.
Linkage analysis
Parametric and nonparametric linkage analyses (two point
and multipoint) were performed using the software SUPER-
LINK V1.6 (22) and GENEHUNTER V1.2, respectively, using the
EASYLINKAGE V5.05 (23) platform. The Kong and Cox
algorithm (24) was used to calculate Zlr scores that are less
conservative where inheritance data are incomplete. Para-
metric analysis was performed using variable penetrances
for both dominant and recessive models. For the dominant
model, initial penetrances used were 0.01, 0.90 and 0.90 for
the wild-type homozygote, mutant heterozygote and
mutant homozygote, respectively. Penetrances of 0.01,
0.01 and 0.80 were used for the recessive model. The initial
disease allele frequency used for the analysis was of 0.001,
equivalent to a population prevalence of 0.2%. A codom-
inant allele frequency algorithmwas used for the analysis, as
suggested in the EASYLINKAGE manual to be the best option
for extended pedigrees.
Because of the extensive phenotypical heterogeneity
within this family, the analysis was performed using three
different models. Model 1 affected status was defined as
those individuals diagnosed as coeliac by biopsy, only. In
model 2, two other individuals with coeliac-like symptoms
(II: 5 and III: 11) were considered affected together with
those diagnosed by biopsy. In model 3, another two
individuals having an elevated AGA (II: 2 and III: 2) were
also defined as affected. Individuals that were screened and
tested negative were assumed to be normal, while those not
tested were assumed to have an unknown phenotype. The
sex-averaged deCode genetic map was used throughout the
study.
HLA typing
HLA typing to detect HLA-DQ2 and/or HLA-DQ8
heterodimers was performed in all family members using
a commercial kit for the detection of DQ CD alleles
(DiaGene S.r.l., Palermo, Italy). A total of 12 PCRs for each
individual were performed as instructed by supplier in a
15-ml reaction followed by agarose gel electrophoresis.
Gene sequencing
All exons, including intron–exon boundaries, and up to
1 kb upstream from the transcriptional start sites of three
genes found within the indicated locus by linkage, were
sequenced. Sequencing was performed in two affected and
two unaffected members (with and without the linked
haplotype). The genes sequenced were those coding for
protectin (CD59) (MIM 107271), CD44 (MIM 107269) and
Apaf-1 interacting protein (APIP) (GeneID 51074), using
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oligonucleotidesdesigned for transcriptsENST00000351554,
ENST00000278385 and ENST00000278359, respectively.
Sequencing reactions were performed using BigDyeTermi-
nators v3.1 and analysed on an ABI 3130 genetic analyser
(Applied Biosystems).
Sequence variants, identified and observed to be inherited
together with the linked haplotype, were further analysed in
all family members either by direct DNA sequencing or by
restriction fragment length polymorphism (RFLP).
Nomenclature used refers to actual nucleotide changes in
the respective polymorphisms.
RNA splicing analysis
A 482- and an 812-bp fragment containing mutated and
wild-type exon 3 and adjacent introns of CD59 and CD44,
respectively, were amplified by PCR using DNA from
family members carrying normal and mutated alleles.
Forward and reverse oligonucleotide primers were designed
harbouring consensus sequences for restriction enzymes
Xho I and Pst I at the 5#end, together with a noncomple-
mentary tail (CD59_F: 5#-CAATGCGGAACTCGAG-
TGTGGTAGTACACACTGGGGCTTAT-3#: CD59_R:
5#-CAATGCGGAACTGCAGCACTGAGGACAAGG-
TCATAACATAGG-3#: CD44_F: 5#-CAATGCGGAAC-
TCGAGACTCAACACTGCTGAACACA-3#: CD44_R:
5#-CAATGCGGAACTGCAGTCCAACACAAACCCG-
TAAAC-3#). The PCR products were initially cloned into
a pGEM-T Easy (Promega Corporation, Madison, WI)
vector and transformed into DH5-a (Invitrogen Ltd,
Paisley, UK). Plasmid DNA was extracted from selected
clones using WizardPlus SV Minipreps DNA purification
system (Promega Corporation), digested and subcloned
into the exon-trapping plasmid pSPL3 (generously donated
by Dr Irene Bottillo, IRCC-CSS, San Giovanni Rotondo
and CSS-Mendel Institute, Rome, Italy). The selected
clones were checked by sequencing for their integrity and
orientation followed by selection of mutated and normal
alleles. Highly purified plasmid DNA for transfections was
prepared using PureYield Plasmid Midiprep System
(Promega Corporation). The plasmid DNA concentration
was measured by spectrophotometry and adjusted to
200 mg/ml.
The purified minigene constructs of both wild-type and
mutated alleles were transfected into HeLa and COS-7 cells
(DSMZ, Braunschweig, Germany). Both cell lines were
cultured in Dulbecco Modified Eagle’s Medium (Sigma,
St Louis, MO) containing 4 mM glutamine, 4.5 g/l glucose,
supplemented with 10% foetal calf serum and incubated at
37C in 5% CO2. Twenty-four hours before transfection,
5  104 cells were seeded into each of a 24-well plate and
incubated overnight in the same conditions described
above. Three replicates for each construct were prepared
together with positive (pSPL3 only) and negative (without
DNA) controls in two separate plates. Transient trans-
fection was performed using Tfx-20 (Promega Corpora-
tion), as recommended, using 1 mg of each construct and
a charge ratio of DNA to transfection reagent of 1:2 (COS-
7) and 1:3 (HeLa). Incubation was carried out at 37C (5%
CO2) for 48 h.
Total cellular RNAwas extracted fromHeLa and COS-7
cells, after 48 h incubation, using SV Total RNA isolation
system (Promega Corporation). First-strand complemen-
tary DNA was synthesised by reverse transcription PCR
using oligo-(dT)16, followed by PCR using specific primers
for the splice donor (SD6) and acceptor (SA2) sites of the
pSPL3 plasmid. The products were analysed using 2%
agarose gel electrophoresis, visualised underUV irradiation
and analysed using IMAGEJ 1.38 software (http://rsb.info.
nih.gov/ij/). All observed transcripts were extracted from
gel and sequenced.
Results
Linkage study
Table 1 shows highest NPL and LOD scores observed
following the initial genome-wide scan in this family, for all
models tested. Chromosome 11p13-12 showed the highest
LOD scores when using both two-point and multipoint
parametric analysis at a slightly reduced penetrance (80%).
The region on chromosome 9q21 showed a lower LOD
score than that of chromosome 11, but similar NPL. A
region of more than 50 cMon chromosome 10 failed to give
consistent results across all models tested. Analysis was
performed using a dominant model with penetrances
ranging from 90 to 50% and 1% phenocopy rate. No
evidence of linkage was observed to other regions including
the HLA locus on chromosome 6 when using both
dominant and recessive models.
High-resolution scan
Sixteen additional markers were added at the indicated loci
on chromosomes 9 (D9S1780, D9S1680), 10 (D10S1709,
D10S200, D10S1786, D10S187, D10S1792, D10S168,
D10S597 and D10S1671) and 11 (D11S871, D11S914,
D11S4101, D11S935, D11S4102 and D11S1911). The spa-
cing between the markers was approximately of 2–5 cM.
NPL and LOD scores obtained after increasing the markers
remained the same as for the initial scan with a slight
increase in marker information (up to 0.99 to marker
D11S1392). The linkage interval on chromosome 11 was
narrowed to a region between 48.21 and 52.95 cM with
marker D11S1392 at 50.94 cM from pTer, showing the
highest NPL/LOD (deCode genetic map). The linkage
interval on both chromosomes 9 and 10 remained the same
even after fine mapping.
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Two inherited haplotypes were observed on chromosomes
11 and 9, with a number of recombinations very close to the
indicated markers. As shown in Figure 1, allele 3 at marker
D11S1392 was inherited identical by descent in all affected
individuals within this family but was not found in most
unaffected members with the exception of individual III: 8.
A haplotype on chromosome 9 (Figure 2) atmarkersD9S167,
D9S1680 andD9S278 (alleles 2-1-3), showeda similarmodeof
inheritance to that of chromosome 11, with the exception of
individual III: 4.
HLA typing
Because no evidence of linkage was observed to the HLA
locus on chromosome 6,HLA typing of all familymembers
was performed to determine whether they were HLA-DQ2
or HLA-DQ8. Table 2 shows the HLA types of all family
members. Thirteen of 17 members carried the HLA-
DQ2 heterodimer (76.5%). Also 88.2% of family mem-
bers carried the allele DQA1*05 and 70.5% had the
DQA1*0201 allele. The youngest affected individual (III:
1) was heterozygous for HLA-DQ2 and DQ8 also carrying
Table 1 Two point and multipoint LOD scores and nonparametric analyses
Marker Chromosome Position (cM)a LOD (two point) Theta LOD (multipoint)b NPL (Zlr)c P Penetrancesd
Model 1
D11S1392 11 50.64 1.29 0.0000 1.66 2.08 (1.65) 0.1250 0.01, 0.80 and 0.80
D10S1731 10 134.96 0.66 0.0000 0.87 3.09 (2.63) 0.0313 0.01, 0.80 and 0.80
D9S167 9 81.01 0.37 0.0500 0.67 2.08 (1.65) 0.1250 0.01, 0.07 and 0.07
Model 2
D11S1392 11 50.64 1.99 0.0000 2.25 4.12 (2.39) 0.0313 0.01, 0.80 and 0.80
D10S1731 10 134.96 1.53 0.0000 0.26 5.27 (3.31) 0.0039 0.01, 0.60 and 0.60
D9S167 9 81.01 1.18 0.0000 1.25 4.12 (2.39) 0.0313 0.01, 0.60 and 0.60
Model 3
D11S1392 11 50.64 2.33 0.0000 2.57 6.21 (2.20) 0.0107 0.01, 0.80 and 0.80
D9S167 9 81.01 1.36 0.0000 1.58 6.21 (2.20) 0.0107 0.01, 0.70 and 0.70
NPL, nonparametric linkage; LOD, logarithm of odds.
a Chromosomal position from pTer using deCode genetic map.
b Highest LOD scores obtained using a dominant model with 90% penetrance (0.01, 0.90 and 0.90).
c Zlr score using Kong and Cox algorithm (21).
d Penetrance frequencies for two-point parametric analysis: phenocopy, mutant heterozygote and mutant homozygote.
Figure 2 Inheritance of STRs on chromosome 9. Affected males and females are shown in black shading; females labelled (?) were reported to have
coeliac-like symptoms. Males and females labelled (N) tested individuals showing no evidence of celiac. One-quarter black-shaded individuals only had
high antigliadin (AGA).Markers shown top to bottom areD9S1122, D9S1780, D9S167, D9S1680, D9S278, D9S1689 andD9S938. Inferred genotypes by
GENEHUNTER are in parentheses.
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the DR4 and DR7 alleles. None of the family members
were carrying the DR3 allele. As shown in Table 2, most
individuals were heterozygous DQ2.2 (DQA1*0201 and
DQB1*02) and DQ7 (DQA1*05 and DQB1*0301/04),
being also DQ2.5 in trans (DQA1*05 and DQB1*02).
There were no differences in the pattern of inheritance of
HLA alleles between affected and nonaffected family
members.
Gene sequencing
A total of 28 genes and hypothetical proteins are found
within the linkage interval between 48 and 53 cM on
chromosome 11p13-12 according to the NCBI map viewer
build 36.2 (Homo sapiens) (http://www.ncbi.nlm.nih.gov).
A number of sequence variants were identified by direct
DNA sequencing in three genes sequenced at this region
(CD59, APIP and CD44) when compared with reference
sequences on NCBI and Ensembl databases. Six variants
were found within the CD44 gene, all of which were already
reported in public databases (rs11033019, rs1071695,
rs3736812, rs1103025, rs9666607 and rs1467558). Two of
these variants (rs9666607 and rs1467558) are found in exons
and result in amino acid changes but were not linked to the
inherited haplotype at this region. On the other hand, a T to
C transition within exon 3 (rs1071695) was found in all
family members carrying the inherited haplotype. This
variant does not result in an amino acid change. Nsp I was
used to determine the frequency of this variant in a random
sample from the general population (n ¼ 248) and in
a group of coeliac patients (all diagnosed by biopsy)
(n ¼ 92). The genotype frequencies observed were 66.5%
CC, 31.5% CT and 2% TT: in the general population
and 69.6% CC, 26.1% CT and 4.3% TT: in the group of
coeliac patients. Both genotype frequencies were in Hardy–
Weinberg equilibrium.
Eight variants were identified within the APIP gene
(rs16926448, rs2016814, rs2016821, rs1326942, rs1326941,
rs2303959, rs2303958 and rs1571133). The A to C trans-
version, found in exon 5 (rs1571133), does not result in an
amino acid change. Another variant within this gene
(rs2016814) was found in almost complete linkage with
Table 2 HLA typing in family members and the GA variant identified in CD59a
Family member Status Risk DQA1 DQB1 DRB1 HLA type CD59 G/A variant
I: 1 Not known High (DQ2.5 in trans) 0201 05 02 0301/04 07/11 DR7/DQ2 GG
DR11/DQ7
II: 1 Normal No risk 05 ND 0301/04 ND 11/12 DR11/DR12/DQ7 GG
II: 2 High AGA High (DQ2.5 in trans) 0201 05 02 0301/04 07/12 DR7/DQ2 GA
DR12/DQ7
II: 3 Affected High (DQ2.5 in trans) 0201 05 02 0301/04 07/11 DR7/DQ2 GA
DR11/DQ7
II: 8 Normal No risk 05 ND 0301/04 ND 11/12 DR11/DR12/DQ7 GG
II: 4 Normal No risk 05 ND 0301/04 ND 11/12 DR11/DR12/DQ7 GG
II: 5 Symptomatic High (DQ2.5 in trans) 0201 05 02 0301/04 07 DR7/DQ2 GA
DQ7
II: 6 Affected Moderate (DQ2.2) 0201 ND 02 ND 07 DR7/DQ2 GA
II: 7 Affected High (DQ2.5 in trans) 0201 05 02 0301/04 07/12 DR7/DQ2 GA
DR12/DQ7
III: 1 Affected Moderate (DQ8) 0201 03 02 0302 07/04 DR7/DQ2 GA
DR4/DQ8
III: 2 High AGA High (DQ2.5 in trans) 0201 05 02 0301/04 07/12 DR7/DQ2 GA
DR12/DQ7
III: 3 Normal High (DQ2.5 in trans) 0201 05 02 0301/04 07/12 DR7/DQ2 GG
DR12/DQ7
III: 4 Normal High (DQ2.5 in trans) 0201 05 02 0301/04 07/11 DR7/DQ2 GG
DR11/DQ7
III: 6 Normal High (DQ2.5 in cis) 05 ND 02 0301/04 07/11/12 DR7/DQ2 GG
DR11/12/DQ7
III: 8 Normal No risk 05 ND 0301/04 ND 11/12 DR11/DR12/DQ7 GA
III: 10 Normal High (DQ2.5 in trans) 0201 05 02 0301/04 07/11 DR7/DQ2 GA
DR11/DQ7
III: 11 Symptomatic High (DQ2.5 in trans) 0201 05 02 0301/04 07/11 DR7/DQ2 GA
DR11/DQ7
AGA, antigliadin; ND, not determined; HLA, human leukocyte antigen.
a Underlined and bold alleles are those increasing risk. DR11/12-DQ7 haplotype (DRB1*11/12, DQA1*05 and DQB1*0301/04); DR7–DQ2 haplotype
(low-risk DQ2.2) – (DRB1*07, DQA1*0201 and DQB1*02). High-risk DQ2.5 (DQA1*05 and DQB1*02) (observed in trans).
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the inherited haplotype, with the exception of individuals
III: 4 and III: 8.
A novel variant (G/A) was identified within exon 3 of the
protectin (CD59) gene. The G to A transition was observed
to be in linkage with the inherited haplotype in our family
(Table 2). This variant is the third nucleotide of the sixth
codon for the signal peptide but does not result in a change
of the amino acid, glycine (GGG > GGA). PCR-RFLP
using restriction enzyme BstY Iwas performed in a random
sample from the population and a group of coeliac patients
as above. This variant was completely absent in the group
of unrelated coeliac patients and only one mutated allele
was identified from 442 chromosomes analysed (0.2%),
with a population frequency of 0.45%. This suggests that
this variant is a rare mutation found only within this family.
To assess the possibilities that this variant might have
a deleterious effect, the on-line application SNPs3D (http://
www.snps3d.org) (25) was used to analyse entropy. An
entropy of 1.25 was obtained giving a 15% chance that
this variant might cause disease against 7.5% to be
nondeleterious.
Analysis of RNA splicing
An on-line bioinformatics tool that calculates free energy to
predict RNA secondary structure was used (http://www.
genebee.msu.su/services/rna2_reduced.html) (26). The re-
sults suggested that both variants within CD44 and CD59
might have an effect on RNA secondary structure. Using
the on-line application FAS-ESS and RESCUE-ESE
(http://genes.mit.edu/fas-ess/) (27), the two regions (CD44
and CD59) were tested for possible exonic splicing silencers
(ESS) and enhancers (ESE). The region in CD44, where the
linked variant was identified, did not show any ESS or
ESE both in normal and in mutated alleles. A hexamer
(FAS-Hex3) consensus sequence (GGAGGG) for an ESS
was only observed in the wild-type allele of CD59 and was
absent in the mutated allele, while two ESEs were observed
(GGAGGA and GAGGAT) in the mutated allele. To test
the hypothesis whether the variants found within both
CD44 andCD59 exonsmight affect the splicingmechanism,
a minigene system was used.
As shown in Figure 3a,b, amplified products of tran-
scripts from pSPL3 minigene system were consistent
between HeLa and COS-7 cell lines. For the variant within
CD44 gene, only one transcript of 395 bp was observed in
both normal and mutated alleles, showing that the C/T
variant does not have any effect on exon skipping.As for the
CD59 gene, two transcripts were observed from both
normal and mutated constructs. The longer transcript
consisted of 346 bp, while the smaller was 209 bp in size
when compared with size marker and the control transcript
from pSPL3 (261 bp). When sequencing both fragments,
the 346 bp product was found to bemade up of the full exon
3 of CD59 with flanking pSPL3 exons on both sides.
Sequencing of the shorter product (209 bp) showed that
exon 3 was spliced 6 bp upstream from the position of the
identified variant, and only a small portion of this exon
formed part of this transcript, while a small part (81 bp) of
the pSPL3 exon was also missing. Sequencing was
performed on both bigger and smaller fragments from
wild-type and mutated constructs and the same results were
obtained. Only a slight difference in band intensities was
observed between the wild-type and mutated alternatively
spliced fragments (209-bp fragments), where the latter had
a slightly higher intensity. Using IMAGEJ 1.38x software,
a slightly higher peak was observed for the smaller PCR
fragment (indicated by an arrow) when compared with that
from the bigger fragment of those transcripts amplified
from mutated constructs (Figure 3d). Measuring peak
height of both fragments, the ratio of the alternatively
spliced fragment to normal transcript (higher peak) was of
0.43 against 0.26 from mutated and wild-type constructs,
respectively, for HeLa cells. This difference was less (0.43 vs
0.36) in mutated and wild-type constructs from COS-7.
Discussion
In this study, suggestive linkage to chromosomes 9q21 and
11p13-12 was observed in a family with high incidence
of CD. Two haplotypes on chromosomes 9 and 11 were
observed to be inherited identical by descent in all affected
members but not in most clinically nonaffected individuals.
A rare variantwithin exon 3 of theCD59 genewas in linkage
with the inherited haplotype.
Although no evidence of linkage was observed to the
HLA locus on chromosome 6, HLA typing showed that
most family members, including clinically normal individ-
uals, carried the haplotype DRB1*07-DQA1*0201,
DQB1*02 (DQ2.2), which does not increase the risk for
CD (28). Risk for disease was high in the majority of
affected family members in the presence of HLA-DQ2.5
(DQA1*05 and DQB1*02) in trans, although this was also
found in clinically normal family members. This shows that
althoughHLA alleles play amajor role in disease, they were
not the only causative factors of disease in this family. From
this family, it is evident that susceptibility for disease was
increased by the presence of both HLA-DQ2.5 and the A
allele in CD59. This observation was supported by three
normal individuals that were HLA-DQ2.5 in trans but that
did not carry the CD59 A allele. On the other hand,
individual II: 6 was affected even though she was typed as
HLA-DQ2.2 in cis, which is considered to be of a moderate
risk, but then she was also carrying the CD59 A allele.
Conversely, individual III: 10 carried both the high-risk
HLA-DQ2.5 and the CD59 variant, but still he was
phenotypically normal. This suggests that other genetic
and/or environmental factors, besides HLA and the CD59
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Figure 3 RNA splicing analysis; (a) and (b) agarose gel of reverse transcription PCR: column (A) phiX; (B and H) CD59 normal allele; (C and I) CD59
mutated allele; (D) CD44 normal allele; (E) CD44mutated allele; (F and J) pSPL3-positive control and (G and K) negative control; (c) schematic diagram of
amplified transcripts observed in agarose gel electrophoresis; (d) scanned images of gels using IMAGEJ 1.38x software for both normal and mutated
constructs. Arrow indicates peak representing the shorter transcript; (e) electropherogram of normally spliced transcript from normal allele. Red arrow
shows position of variant; (f) electropherogram of transcript from mutated allele, showing exon skipping.
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variant, might have an effect on the penetrance of disease in
this family.
A recent study performed in Bedouin kindred also
reported absence of linkage to the HLA locus, where
a higher frequency of high-risk HLA alleles was observed in
affected members, thus negative linkage was probably
because of a lack of distinction between alleles that were
identical by descent from those that were identical by state
(5). Besides this, there could be various reasons why we
failed to detect linkage at the HLA locus including low
marker density (closest marker D6S1051 being approxi-
mately 4 cM away), no difference in the inheritance pattern
of HLA alleles between affected/nonaffected members and
because in this family risk for disease was increased byHLA
alleles being in trans and not in cis. This could be a weak
point when performing linkage analysis in a single pedigree
and where risk for disease is increased by contribution of
different alleles found in trans rather than in cis.
The locus on chromosome 9q21 was not reported in
previous linkage studies for CD. This regionwas only linked
to inflammatory diseases such as ankylosing spondylitis and
multiple sclerosis (29, 30). In our study, no linkage was
found to other previously associated loci with CD as 11q,
4q27, 5q31 and the CTLA4-ICOS region on chromosome 2
(2, 12, 17, 31, 32).
The region on chromosome 11 confirmed reported results
from linkage studies performed in 50 British families (10)
and of an earlier study performed by Zhong et al. (33), but
no genes were further studied at this region. On the other
hand, linkage to this region was not replicated in other
studies performed later (3, 8, 34). Linkage at 11p12 was
observed with other inflammatory disorders such as
inflammatory bowel disease, rheumatoid arthritis and
osteoporosis (35–37).
A number of variants were identified within the CD44
and APIP genes, found within the linkage interval on
chromosome 11p13-12. CD44 is the main hyaluronate cell
surface receptor, which plays an important role in the
selective migration of lymphocytes from the blood stream
into the lymphatic system (38). Different isoforms are found
in different tissues as a result of the extensive alternative
splicing of its gene (39, 40). Expression of CD44 was
observed to be increased in the intestinal mucosa of coeliac
patients especially those with active disease (41). We failed
to show any effect of one of the identified variants on pre-
mRNA splicing, although this does not exclude the possible
involvement of this gene in disease because this variant
might be in linkage disequilibrium with another functional
variant found in regions that were not sequenced. Similarly,
none of the variants identified within the regions sequenced
of the APIP gene were linked with the inherited haplotype.
APIP suppresses apoptosis by binding to Apaf-1 and thus
preventing further activation through caspase-9 (42).
Because apoptosis is known to be responsible for the
flattening of the intestinal epithelium and depletion of
peripheral blood lymphocytes in coeliac individuals (43, 44),
possible mutations within the APIP gene that render it
inactive might lead to an increased intestinal damage
because of increased apoptosis.
The identification of the G/A variant within exon 3 of the
CD59 gene is important for the identification of novel
mechanisms that are involved in the pathogenesis of CD, in
this case the complement system. Protectin (CD59) is
a membrane glycoprotein widely expressed in a number of
tissues, which protects cells from lysis after the formation of
the C5b-9 membrane attack complex (MAC) of comple-
ment. Its gene is similar to that of the murine lymphocyte
antigen Ly-6 protein (45), while a conserved segment of the
protein between residues 42–58 of human CD59 is
responsible for the species restricted inhibitory function of
MAC (46). The role played by protectin in the human
intestinal mucosa as well as in other tissues was reported by
a number of investigators (47–49). Expression of CD59
together with CD55 was upregulated in epithelial cells but
not in parietal cells of patients with chronic gastritis, CD
and inflammatory bowel disease (48). These two molecules
were also highly expressed in normal colonic epithelium,
probably to protect it from the constant complement
activation caused by the presence of the normal flora in
this region. Conversely, CD59 expression was reduced in
affected epithelium of patients with Crohn’s disease and
ulcerative colitis but was normal in nonaffected areas, thus
increasing the vulnerability of the affected areas to
complement lysis (47). These observations show the
importance of CD59 in protecting the intestinal mucosa
from complement and suggest thatmutationswithin its gene
might lead to an increased intestinal damage in patients with
CD. A higher degree of intestinal damage increases the
chance for an individual carrying a high-risk HLA group to
be phenotypically affected and to seek medical attention,
following activation of the immune response on exposure
and antigen presentation of gluten.
Because the variant identified in this study did not result
in an amino acid change, we hypothesised that it could affect
the splicing mechanism by either altering the secondary
structure of pre-mRNAor else by affecting binding of trans-
acting splicing factors (27). The loss of an ESS and
introduction of two possible ESEs, as described above, also
indicate that splicing might be affected by this novel variant
in CD59. Aberrant splicing was reported to be caused by
both missense or silent mutations and by variants found
within introns of a number of genes responsible for other
human diseases including cystic fibrosis, neurofibromatosis
type I and frontotemporal dementia (50–52). A common
problem encountered when studying RNA is to obtain
samples from the affected tissue itself to avoid obtaining
misleading results because of tissue-specific gene expression.
Besides affectingRNAsplicing, synonymous variantsmight
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affect timing of cotranslational folding when a frequently
used codon is replacedby a rare codonpossiblybecauseof the
abundance of transfer RNApresent in cells that correlates to
codon usage in a tissue-specific manner (53, 54).
In conclusion, our results suggest the involvement of
other inflammatory genes present on chromosome 11p13-12
in the pathogenesis of coeliac in a family with high incidence
of CD. These findings have the potential to add to our
understanding of the complex physiology of CD and can
lead to further identification of potential gene candidates
and innovative individualised therapeutic approaches.
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